Cardiovasculaire Geneeskunde.nl

NOACs RWE

Overzicht van studies naar ervaringen met non-VKA orale anticoagulantia (NOACs) bij patiënten met atriumfibrilleren in de dagelijkse klinische praktijk (‘real world evidence’). We zullen dit overzicht wanneer relevant blijven aanvullen.

5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry

Tittl L, Marten S, Naue C, et al., Thromb Res. 2021

22 apr. 2021

Tittl L, Marten S, Naue C, et al. Thromb Res. 2021;202:24-30. doi: 10.1016/j.thromres.2021.03.004.

Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study

14 sep. 2020

Paschke LM, Klimke K, Altiner A. et al. BMC Medicine (2020) 18:254, doi.org/10.1186/s12916-020-01695-7

Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study

25 aug. 2020

de Groot JR, Weiss TW, Kelly P, et al. Eur Heart J Cardiovasc Pharmacother, doi:10.1093/ehjcvp/pvaa079

Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study

17 juni 2020

Colonna P, von Heymann C, Santamaria A, et al. Clin Cardiol. 2020;1–12, DOI: 10.1002/clc.23379

Rates, management and outcome of bleeding complications during edoxaban therapy in daily care – results from the DRESDEN NOAC REGISTRY

4 mei 2020

Beyer-Westendorf J , Marten S, Naue C, et al. Thrombosis Research 2020, doi.org/10.1016/j.thromres.2020.03.021

Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish nationwide cohort

5 dec. 2019

Nielsen PB, Larsen TB, Skjøth F, et al. Eur Heart J Cardiovasc Pharmacother. 2019, doi: 10.1093/ehjcvp/pvz070

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)

22 juli 2019

De Caterina R, Kelly P, Monteiro P et al. BMC Cardiovascular Disorders 2019;19:165

Real-life Performance of Edoxaban in Elderly Patients With Atrial Fibrillation: a Multicenter Propensity ScoreeMatched Cohort Study

2 juli 2019

Russo V, Attena E, Mazzone C et al., Clinical Therapeutics 2019

Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation

Graham DJ, Baro E, Zhang R et al.

7 mrt. 2019

Graham DJ, Baro E, Zhang R et al., Am J Med. 2019.

Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation

Själander S, Sjögren V, Renlund H et al.,

22 aug. 2018

Själander S, Sjögren V, Renlund H et al., Thromb Res. 2018 May 17;167:113-118

Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation

Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V et al.

22 aug. 2018

Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V et al., Am J Cardiol. 2018 Jun 2

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Nonvalvular Atrial fibrillation Patients with a Non-Sex-Related CHA2DS2-VASc Score of 1

Coleman CI, Turpie AGG, Bunz TJ et al., Eur Heart J Cardiovasc Pharmacother. 2018

31 juli 2018

Coleman CI, Turpie AGG, Bunz TJ et al., Eur Heart J Cardiovasc Pharmacother. 2018

3' Educatie

Real-life NOAC data; zinloze publicaties om snel te vergeten…?

3' educatie - 4 okt. 2017 - Prof. dr. Menno Huisman / prof. dr. Freek Verheugt

Wat kunnen de antistollingspolikliniek en de huisarts doen voor de AF-patiënt?

3' educatie - 10 mei 2017 - Nijmegen - Dr. Marc Brouwer en Stijn van Vugt

10' Educatie

NOAC’s bij ouderen met polyfarmacie

10' educatie - 6 mrt. 2017 - Radboudumc, Nijmegen - Dr. Marc Brouwer - Radboudumc, Nijmegen

15' Educatie

FOCUS: Plaatsbepaling van real world data bij antistollingbehandeling

15' educatie - 4 sep. 2017 - Nieuwegein - Prof. dr. Jan Tijssen, dr. Michiel Coppens, dr. Ron Pisters